Abstract: Objective The aim of this study was to investigate changes of urine microalbumin(U-mAl), serum hemoglobin Alc (HbA1c) and thyroid hormones in patients with non-alcoholic fatty liver disease (NAFLD) and concomitant type 2 diabetes mellitus (T2DM). Methods 91 patients with NAFLD and T2DM [non-alcoholic fatty liver (NAFL) in 56 cases,non-alcoholic steatohepatitis (NASH) in 23 cases and cirrhosis in 12 cases] and 91 patients with T2DM were encountered in our hospital between January 2019 and January 2024, serum thyroid stimulating hormone (TSH), tetraiodothyronine(T4) and FT4 levels were assayed by RIA, and fasting blood glucose (FBG), HbAlC, fasting insulin(FINS) and U-mAllevel were routinely detected. Results FBG, serum FINS, HOMA-IR and HbAlC levels in patients with NAFLD and T2DM were (7.6±1.0)mmol/L, (12.6±2.7)μIU/mL, (4.3±1.1) and (8.2±0.9)%, all much higher than [(7.1±1.3)mmol/L, (9.4±3.1)μIU/mL, (3.0±1.3) and (7.0±1.2)%, respectively, P＜0.05] in patients with T2DM; U-mAl and serum T4 levels in patients with NAFLD and T2DMwere(71.6±10.1)mg/L and (134.7±16.6)nmol/L, both significantly higher than [(40.2±10.8)mg/L and (119.0±14.9)nmol/L, P＜0.05], while serum TSH and FT4 were (2.1±0.7)mU/L and (12.4±1.7)pmol/L, both significantly lower than [(3.5±0.7)mU/L and (16.8±3.0)pmol/L, P＜0.05] in patients with T2DM; there were no significant differences as respect to serum fat levels between the two groups (P>0.05). Conclusion U-mAl and serum thyroid hormone levels in patients with NAFLD and concomitant T2DM could elevate, which might sophisticate clinical management in this circumstances.

Key words: Non-alcoholic fatty liver disease, Type 2 diabetes mellitus, Urine microalbumin, Hemoglobin Alc, Thyroid hormone